Patients with AML and an IDH2-R172 mutation exhibit a unique initial response to intensive chemotherapy induction
Abstract: The utility of a midcycle bone marrow biopsy (BMB) for early assessment of response in patients with acute myeloid leukemia (AML) after intensive chemotherapy (IC) induction is contested. Even when challenged, there is little consideration as to the possibility of different response dynami...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | Blood Advances |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2473952925002071 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849431128381849600 |
|---|---|
| author | Meira Yisraeli Salman Alexander R. Terry Andriy Derkach David Nemirovsky Kuo-Kai Chin Yannis K. Valtis Leora Boussi Theresa Spivey Wenbin Xiao Christopher Famulare Jenna Ciervo Jacob M. Rowe Martin S. Tallman Eytan M. Stein |
| author_facet | Meira Yisraeli Salman Alexander R. Terry Andriy Derkach David Nemirovsky Kuo-Kai Chin Yannis K. Valtis Leora Boussi Theresa Spivey Wenbin Xiao Christopher Famulare Jenna Ciervo Jacob M. Rowe Martin S. Tallman Eytan M. Stein |
| author_sort | Meira Yisraeli Salman |
| collection | DOAJ |
| description | Abstract: The utility of a midcycle bone marrow biopsy (BMB) for early assessment of response in patients with acute myeloid leukemia (AML) after intensive chemotherapy (IC) induction is contested. Even when challenged, there is little consideration as to the possibility of different response dynamics among genetically defined subgroups. Clinical observations led to the hypothesis that patients with AML and mutations in IDH2-R172 (R172-m) exhibit particularly slow blast reduction after IC induction. The purpose of this study was to analyze response kinetics of patients with R172-m to IC and compare the dynamics to patients with AML and IDH2-R140 mutations (R140-m). A retrospective single-center analysis was conducted among patients with newly diagnosed IDH2-mutated AML who received IC induction. Dynamics of blast reduction were compared and correlated with outcomes. A total of 52 patients were identified; 33 with R140-m and 19 with R172-m. Patients with R172-m had significantly higher midcycle BMB median blast count (70% vs 5%; P < .001), and their BMBs were slightly more cellular (P = .045). Among the R140-m, 58% had ≤5% blasts vs 0 of the R172-m. Furthermore, it took significantly longer for patients with R172-m to achieve blast clearance (≤5% blasts in BMB) compared to those with R140-m (P = .017). However, there was no difference in overall survival between the 2 groups, and outcomes were similar and favorable. This type of slow blast reduction has only previously been described in patients with acute promyelocytic leukemia. These findings suggest judicial application of reinduction strategies in this subgroup and warrant further investigation. |
| format | Article |
| id | doaj-art-77023079d6b440e8938befe3a3da3b1f |
| institution | Kabale University |
| issn | 2473-9529 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Blood Advances |
| spelling | doaj-art-77023079d6b440e8938befe3a3da3b1f2025-08-20T03:27:44ZengElsevierBlood Advances2473-95292025-07-019133213322210.1182/bloodadvances.2024015324Patients with AML and an IDH2-R172 mutation exhibit a unique initial response to intensive chemotherapy inductionMeira Yisraeli Salman0Alexander R. Terry1Andriy Derkach2David Nemirovsky3Kuo-Kai Chin4Yannis K. Valtis5Leora Boussi6Theresa Spivey7Wenbin Xiao8Christopher Famulare9Jenna Ciervo10Jacob M. Rowe11Martin S. Tallman12Eytan M. Stein13Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Hematology, Shaare Zedek Medical Center, Jerusalem, IsraelLeukemia Service, Memorial Sloan Kettering Cancer Center, New York, NYLeukemia Service, Memorial Sloan Kettering Cancer Center, New York, NYLeukemia Service, Memorial Sloan Kettering Cancer Center, New York, NYLeukemia Service, Memorial Sloan Kettering Cancer Center, New York, NYLeukemia Service, Memorial Sloan Kettering Cancer Center, New York, NYLeukemia Service, Memorial Sloan Kettering Cancer Center, New York, NYLeukemia Service, Memorial Sloan Kettering Cancer Center, New York, NYLeukemia Service, Memorial Sloan Kettering Cancer Center, New York, NYLeukemia Service, Memorial Sloan Kettering Cancer Center, New York, NYLeukemia Service, Memorial Sloan Kettering Cancer Center, New York, NYDepartment of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel; Department of Hematology and BMT, Rambam Health Care Campus and Technion, Israel Institute of Technology, Haifa, IsraelLeukemia Service, Memorial Sloan Kettering Cancer Center, New York, NYLeukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY; Correspondence: Eytan M. Stein, Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 530 E 74th St, New York, NY 10021;Abstract: The utility of a midcycle bone marrow biopsy (BMB) for early assessment of response in patients with acute myeloid leukemia (AML) after intensive chemotherapy (IC) induction is contested. Even when challenged, there is little consideration as to the possibility of different response dynamics among genetically defined subgroups. Clinical observations led to the hypothesis that patients with AML and mutations in IDH2-R172 (R172-m) exhibit particularly slow blast reduction after IC induction. The purpose of this study was to analyze response kinetics of patients with R172-m to IC and compare the dynamics to patients with AML and IDH2-R140 mutations (R140-m). A retrospective single-center analysis was conducted among patients with newly diagnosed IDH2-mutated AML who received IC induction. Dynamics of blast reduction were compared and correlated with outcomes. A total of 52 patients were identified; 33 with R140-m and 19 with R172-m. Patients with R172-m had significantly higher midcycle BMB median blast count (70% vs 5%; P < .001), and their BMBs were slightly more cellular (P = .045). Among the R140-m, 58% had ≤5% blasts vs 0 of the R172-m. Furthermore, it took significantly longer for patients with R172-m to achieve blast clearance (≤5% blasts in BMB) compared to those with R140-m (P = .017). However, there was no difference in overall survival between the 2 groups, and outcomes were similar and favorable. This type of slow blast reduction has only previously been described in patients with acute promyelocytic leukemia. These findings suggest judicial application of reinduction strategies in this subgroup and warrant further investigation.http://www.sciencedirect.com/science/article/pii/S2473952925002071 |
| spellingShingle | Meira Yisraeli Salman Alexander R. Terry Andriy Derkach David Nemirovsky Kuo-Kai Chin Yannis K. Valtis Leora Boussi Theresa Spivey Wenbin Xiao Christopher Famulare Jenna Ciervo Jacob M. Rowe Martin S. Tallman Eytan M. Stein Patients with AML and an IDH2-R172 mutation exhibit a unique initial response to intensive chemotherapy induction Blood Advances |
| title | Patients with AML and an IDH2-R172 mutation exhibit a unique initial response to intensive chemotherapy induction |
| title_full | Patients with AML and an IDH2-R172 mutation exhibit a unique initial response to intensive chemotherapy induction |
| title_fullStr | Patients with AML and an IDH2-R172 mutation exhibit a unique initial response to intensive chemotherapy induction |
| title_full_unstemmed | Patients with AML and an IDH2-R172 mutation exhibit a unique initial response to intensive chemotherapy induction |
| title_short | Patients with AML and an IDH2-R172 mutation exhibit a unique initial response to intensive chemotherapy induction |
| title_sort | patients with aml and an idh2 r172 mutation exhibit a unique initial response to intensive chemotherapy induction |
| url | http://www.sciencedirect.com/science/article/pii/S2473952925002071 |
| work_keys_str_mv | AT meirayisraelisalman patientswithamlandanidh2r172mutationexhibitauniqueinitialresponsetointensivechemotherapyinduction AT alexanderrterry patientswithamlandanidh2r172mutationexhibitauniqueinitialresponsetointensivechemotherapyinduction AT andriyderkach patientswithamlandanidh2r172mutationexhibitauniqueinitialresponsetointensivechemotherapyinduction AT davidnemirovsky patientswithamlandanidh2r172mutationexhibitauniqueinitialresponsetointensivechemotherapyinduction AT kuokaichin patientswithamlandanidh2r172mutationexhibitauniqueinitialresponsetointensivechemotherapyinduction AT yanniskvaltis patientswithamlandanidh2r172mutationexhibitauniqueinitialresponsetointensivechemotherapyinduction AT leoraboussi patientswithamlandanidh2r172mutationexhibitauniqueinitialresponsetointensivechemotherapyinduction AT theresaspivey patientswithamlandanidh2r172mutationexhibitauniqueinitialresponsetointensivechemotherapyinduction AT wenbinxiao patientswithamlandanidh2r172mutationexhibitauniqueinitialresponsetointensivechemotherapyinduction AT christopherfamulare patientswithamlandanidh2r172mutationexhibitauniqueinitialresponsetointensivechemotherapyinduction AT jennaciervo patientswithamlandanidh2r172mutationexhibitauniqueinitialresponsetointensivechemotherapyinduction AT jacobmrowe patientswithamlandanidh2r172mutationexhibitauniqueinitialresponsetointensivechemotherapyinduction AT martinstallman patientswithamlandanidh2r172mutationexhibitauniqueinitialresponsetointensivechemotherapyinduction AT eytanmstein patientswithamlandanidh2r172mutationexhibitauniqueinitialresponsetointensivechemotherapyinduction |